The perfect storm.

Could it be that when Benitec gets efficacy and can actually attract some big attention that a bidding war can take place...like with Galapagos may end up dealing with since both J&J and Abbvie are poised to fight for their Oral RA drug.
Biotech companies are getting more attention and money as novel therapies are coming out. I just hope we can get some data before we completely miss the boat.  But with Hep B still looming without a cure, hep C without a cost effective treatment that's pan-geno, and with positive motion with AMD...I personally believe we are far from out of the race. And if we can score a partner or more money, we can explore more indications and push the current ones further into the clinic.  Our day will come...it's just painful to watch some of the floundering and fumbling over the years.

http://www.fiercebiotech.com/story/...gen-sanofiregeneron-prep-price-war/2015-05-26